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ABSTRACT 
Glaucoma has been highlighted as a priority eye disease by the World Health Organization’s global initiative to eliminate 
avoidable blindness by the year 2020. Glaucoma is defined as an optic neuropathy, characterized for loss of visual field and injury 
of the optic nerve. However the mechanism leading to the disease is still unclear. Factors that are responsible for it include 
glutamate-induced neurotoxicity, nitric oxide based damage, disruption of neurotrophic factor transport and immune-induced 
neuro destruction. At present treatment options primarily aim at decreasing intra-ocular pressure (IOP) by utilizing 
pharmacological agents, laser therapy and surgery. Gaining a better understanding of the pathogenesis can aid in the development 
of new treatment options and, perhaps, even a cure for glaucoma. Since there is no cure for Glaucoma, early detection and 
treatment can slow or prevent further vision lossThis article discusses the pathophysiology of glaucoma, its detection, diagnosis 
monitoring and treatment.  
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INTRODUCTION 
The glaucoma is defined, currently, as an optic neuro-
pathy, characterized for loss of visual field and injury 
of the optic nerve, being the increase of the intra-ocular 
pressure (IOP) considered as a risk factor. In glaucoma, 
the eye’s drainage system becomes clogged so the 
intraocular fluid cannot drain
1
. As the fluid builds up, it 
causes pressure to build inside the eye. High pressure 
damages the sensitive optic nerve and results in vision 
loss
2
.  
Glaucoma is not a single clinical entity but a group of 
ocular diseases with various causes that ultimately are 
associated with a progressive optic neuropathy leading 
to loss of vision. 
At present 8.4 million persons worldwide are 
bilaterally blind as a result of glaucoma (4,472.083 
open angle glaucoma (OAG) and 3,936,241 angle 
closure glaucoma (ACG). Glaucoma is the second 
worldwide cause of blindness, making it the second 
leading cause of bilateral blindness. Glaucoma is 
termed as “silent thief of sight”, the blindness caused 
by this disease is irreversible. 
Glaucoma affects people of all ages, from babies to 
older adults
3
. Although everyone is at risk for  
glaucoma, those at higher risk include people over age 
60, relatives of people with glaucoma, people of 
African descent, people with diabetes, people with 
extensive use of steroids, and people who have 
elevated eye pressure
4
.  
Sight loss resulting from glaucoma cannot be reversed. 
However, early detection and careful, lifelong 
treatment with medication or surgery can maintain 
vision
5
. 
In the most common form of glaucoma, buildup of 
fluid pressure happens very slowly. Often, there are no 
uncomfortable or painful symptoms and can suddenly 
result in vision loss. 
Structure of the Eye ball
 
The eye is our organ of sight. It is not shaped like a 
perfect sphere, composed of the anterior segment and 
the posterior segment. The anterior segment is made up 
of the cornea, iris and lens
6
. 
 
Figure 1: Normal eye anatomy 
Cornea: The cornea is transparent and more curved, 
and is linked to the larger posterior segment, composed 
of the vitreous, retina, choroid and the outer white shell 
called the sclera, clear front window of the eye that 
transmits and focuses light into the eye. The cornea is 
typically about 11.5 mm (0.3 in) in diameter, and 1/2 
mm (500 um) in thickness near its center
7
. 
Iris: colored part of the eye that helps regulate the 
amount of light that enters. The iris is the pigmented 
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circular structure concentrically surrounding the center 
of the eye, the pupil, which appears to be black. The 
iris of the eye functions like the diaphragm of a 
camera, controlling the amount of light reaching the 
back of the eye by automatically adjusting the size of 
the pupil
8
. 
Pupil: dark aperture in the iris that determines how 
much light is let into the eye. The size of the pupil, 
which controls the amount of light entering the eye, is 
adjusted by the iris' dilator and sphincter muscles. After 
passing through the cornea, light travels through the 
pupil (the black dot in the middle of the eye)
9
. 
Lens: transparent structure inside the eye that focuses 
light rays onto the retina. Behind the iris sits the lens. 
By changing its shape, the lens focuses light onto the 
retina. Through the action of small muscles (called the 
ciliary muscles), the lens becomes thicker to focus on 
nearby objects and thinner to focus on distant objects
10
. 
Retina: nerve layer that lines the back of the eye, 
senses light, and creates electrical impulses that travel 
through the optic nerve to the brain. The retina contains 
the cells that sense light (photoreceptors) and the blood 
vessels that nourish them
11
.  
 Macula: The most sensitive part of the retina is a 
small area called the macula, which has millions of 
tightly packed photoreceptors (the type called cones). 
The high density of cones in the macula makes the 
visual image detailed, just as a high-resolution digital 
camera has more megapixels
12
. 
Optic nerve: connects the eye to the brain and carries 
the electrical impulses formed by the retina  
to the visual cortex of the brain. The photoreceptors in 
the retina convert the image into electrical signals, 
which are carried to the brain by the optic nerve
13
.  
Each photoreceptor is linked to a nerve fiber. The 
nerve fibers from the photoreceptors are bundled 
together to form the optic nerve. The optic disk, the 
first part of the optic nerve, is at the back of the eye. 
There are two main types of photoreceptors: cones and 
rods. 
i). Cones are responsible for sharp, detailed central 
vision and color vision and are clustered mainly in the 
macula
14
. 
ii). Rods are responsible for night and peripheral (side) 
vision. Rods are more numerous than cones and much 
more sensitive to light, but they do not register color or 
contribute to detailed central vision as the cones do. 
Rods are grouped mainly in the peripheral areas of the 
retina
15
. 
Vitreous: clear, jelly-like substance that fills the 
middle of the eye
16
. 
 
TYPES OF GLAUCOMA  
Glaucoma can be classified according to anterior 
chamber angle findings and the presence or absence of 
disease (states) causing elevated IOP and 
accompanying factors. Different types of glaucoma are 
identified, that is generally classified into open angle or 
angle closure glaucoma based on the width of the angle 
between the cornea and the iris
17
. 
Open-Angle Glaucoma  
Open-angle glaucoma, the most common form of 
glaucoma, accounting for at least 90% of all glaucoma 
cases:  is caused by the slow clogging of the drainage 
canals, resulting in increased eye
 
pressure has a wide 
and open angle between the iris and cornea  develops 
slowly and is a lifelong condition  has symptoms and 
damage that are not noticed
11
.  
There are no early warning signs of open-angle 
glaucoma (also called primary or chronic glaucoma). It 
develops slowly and sometimes without noticeable 
sight loss for many years
18
. Most people who have 
open-angle glaucoma feel fine and do not notice a 
change in their vision. That is why regular eye exams 
are so important. With early detection, open-angle 
glaucoma usually responds well to medication.  
However, it will be very important that you carefully 
follow your medication regimen to continually 
preserve healthy eye pressure and prevent vision loss
19
.  
Angle- Closure Glaucoma  
The other main type of glaucoma is called angle-
closure glaucoma. It is also called acute glaucoma or 
narrow-angle glaucoma. This type is rare and: is caused 
by blocked drainage canals, resulting in a sudden rise 
in intraocular pressure  has a closed or narrow angle 
between the iris and cornea develops very quickly has 
symptoms and damage that are usually very noticeable  
demands immediate medical attention
20
. The closed 
angle prevents fluid from reaching the drainage canals. 
As a result, the intraocular pressure rises very quickly, 
causing a painful attack in the eye. The eye may appear 
red. Treatment of angle-closure glaucoma usually 
involves either laser or conventional surgery to remove 
a small portion of the bunched-up outer edge of the iris. 
Surgery helps unblock the drainage canals so that the 
extra fluids can drain
21
.  
Other types of Glaucoma  
Most of the other types of glaucoma are variations  
of open-angle or angle-closure types. These types can 
occur in one or both of your eyes
22
.  
Secondary Glaucoma  
It can occur as the result of an eye injury, 
inflammation, tumor, in advanced cases of cataract or 
diabetes or by certain drugs such as steroids. This form 
of glaucoma may be mild or severe
23
.  
Pigmentary Glaucoma  
Is a form of secondary open-angle glaucoma, occurring 
when the pigment granules that are in the back of the 
iris (the colored part of the eye) break into the clear 
fluid produced inside the eye. These tiny pigment 
granules flow toward the drainage canals in the eye and 
slowly clog them, causing eye pressure to rise. 
Treatment usually includes medications, laser surgery, 
or filtering surgery
24
.  
Normal-tension Glaucoma (NTG)  
It is also called low-tension or normal-pressure 
glaucoma. In this type of glaucoma, the optic nerve is 
damaged even though the intraocular pressure is not 
very high. The cause is unknown. People at higher risk 
for normal tension glaucoma have a family history of 
normal-tension glaucoma, are of Japanese ancestry, or 
have a history of systemic heart disease, such as 
irregular heart rhythm
25
. 
Congenital Glaucoma  
Occurs in babies when there’s incorrect or incomplete 
development of the eye’s drainage canals during the 
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prenatal period. This is a rare condition that may be 
inherited. Exfoliative Glaucoma occurs when a flaky, 
dandruff-like material peels off the outer layer of the 
lens within the eye. The material collects in the angle 
between the cornea and iris and can clog the drainage 
system of the eye, causing eye pressure to rise
26
.  
Congenital glaucoma can often be corrected with 
microsurgery.  
Neovascular Glaucoma  
The abnormal formation of new blood vessels on the 
iris and over the eye’s drainage channels can cause this 
form of open-angle glaucoma. Neovascular glaucoma 
is always associated with other abnormalities, most 
often diabetes. It never occurs on its own. The new 
blood vessels block the eye’s fluid from exiting 
through the trabecular meshwork (the eye’s drainage 
canals), causing an increase in eye pressure
27
.  
Uveitic Glaucoma  
Uveitis is swelling and inflammation of the uvea, the 
middle layer of the eye. The uvea provides most of the 
blood supply to the retina. Increased eye pressure in 
uveitis can result from the inflammatory process itself 
or the medication (steroids) used to treat it
28
.  
Traumatic Glaucoma  
Injury to the eye may cause traumatic glaucoma. This 
form of open-angle glaucoma can occur immediately 
after the injury or develop years later. It can be caused 
by blunt injuries that bruise the eye (called blunt 
trauma) or by injuries that penetrate the eye
29
.  
 
DIAGNOSIS 
 
In less common kinds of glaucoma, symptoms can be 
more severe. These symptoms can include:  
• Hazy vision.  
• The appearance of rainbow-colored circles around 
bright lights.  
• Sudden sight loss. 
• Eye and head pain  
• Nausea or vomiting. 
To be safe and accurate, following diagnostic exams 
should be used for glaucoma diagnosis:  
1. Tonometry- The inner eye pressure (IOP)
30
.   
2. Ophthalmoscopy or dilated eye exam- The shape 
and color of the optic nerve.  
3. Perimetry test- The complete field of vision.  
4. Gonioscopy- The angle in the eye where the iris 
meets the cornea
31
.  
5.  Pachymetry- Thickness of the cornea.  
It is also important to interview the patient concerning 
subjective symptoms, with symptoms such as blurred 
vision, irisopsia, eye pain, headache, and hyperemia 
indicating a possible history of acute glaucoma attacks. 
Patient’s family history and patients with a family 
history of glaucoma in particular should be asked about 
visual function damage in blood relatives
32
.  
 
TREATMENT  
The purpose of glaucoma therapy at the present time is 
to maintain the patient’s visual function. At present, 
based on the evidence, the only reliable treatment for 
glaucoma is to decrease IOP. Improvement of ocular 
blood flow and direct neuroprotection have attracted 
attention as new therapeutic methods involving factors 
other than IOP, and these may become innovative 
therapeutic options in the future. 
 Medication  
  Laser use and surgery  
Medication  
Eye drops
 
Glaucoma treatment often starts with eye drops. These 
can help decrease eye pressure by improving fluid 
drains from eye
33
. Prescription eye drop medications 
include- 
i. Prostaglandins. These increase the outflow of the 
fluid in eye and reduce pressure
34
. 
Examples- latanoprost (Xalatan) and bimatoprost 
(Lumigan).  
Side effects- mild reddening and stinging of the eyes, 
darkening of the iris, changes in the pigment of the 
eyelashes or eyelid skin, and blurred vision. 
ii. Beta blockers. These reduce the production of fluid 
in eye, thereby lowering the pressure in eye
35
.  
Examples-  timolol and betaxolol. 
Side effects- difficulty breathing, slowed heart rate, 
lower blood pressure, impotence and fatigue. 
iii. Alpha-adrenergic agonists. These reduce the 
production of aqueous humor and increase outflow of 
the fluid in eye
36
. 
 Examples- apraclonidine (Iopidine) and brimonidine 
(Alphagan).  
Side effects- an irregular heart rate; high blood 
pressure; fatigue; red, itchy or swollen eyes; and dry 
mouth. 
iv. Carbonic anhydrase inhibitors. Rarely used for 
glaucoma, these drugs may reduce the production of 
fluid in eye
37
.  
Examples- dorzolamide (Trusopt) and brinzolamide 
(Azopt).  
Side effects- metallic taste, frequent urination, and 
tingling in the fingers and toes. 
v. Miotic or cholinergic agents. These increase the 
outflow of fluid from eye
38
. 
 Example- pilocarpine. 
Side effects- smaller pupils, possible blurred or dim 
vision, and nearsightedness. 
Oral medications
 
If eyedrops alone don't bring eye pressure down to the 
desired level, usually a carbonic anhydrase inhibitors 
are prescribed as an oral medication. Possible side 
effects include frequent urination, tingling in the 
fingers and toes, depression, stomach upset, and kidney 
stones
39
. 
Laser use and surgery  
Other treatment options include laser therapy and 
various surgical procedures. Possible complications 
include pain, redness, infection, inflammation, 
bleeding, abnormally high or low eye pressure, and 
loss of vision. Some types of eye surgery may speed 
the development of cataracts. Surgery is the main 
treatment method for angle-closure glaucoma and 
congenital glaucoma, because it may be the only way 
that the blocked or incorrectly formed drainage canals 
can be opened. In cases of open-angle glaucoma, 
surgery is usually considered when the maximum 
amount of medication is not controlling eye pressure or 
when patient cannot tolerate the side effects of the 
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medication. The primary strategy involves “burning” 
holes in various areas within the eyes including the 
ciliary and the pigmented trabecular meshwork cells. 
The benefits include being noninvasive, needing less 
patient compliance and lowering the possibility of 
infection or bleeding
40
.  
Types of laser surgery 
1. Argon Laser Trabeculoplasty (ALT)  
Used for primary open-angle glaucoma. Laser beam is 
aimed at the fluid drainage channels helping the 
drainage system work
41
.  
2. Selective Laser Trabeculoplasty (SLT)  
Uses a laser that works at very low levels. Treats 
specific cells and leaves the mesh-like drainage canals 
surrounding the iris intact. Because it affects only 
certain cells without causing collateral tissue damage, 
SLT can potentially be repeated
42
. 
3. Laser Peripheral Iridotomy (LPI)  
LPI is frequently used to treat angle-closure  
glaucoma, in which the angle between the iris and the 
cornea is too small and blocks fluid flow out of the eye. 
A laser creates a small hole in the iris to allow fluid 
drainage
43
. 
4. Micropulse Laser Trabeculoplasty (MLT)  
Provides the same pressure-lowering effects as SLT 
and ALT. Uses a specific diode laser to deliver laser 
energy in short microbursts.  
5. Laser Cyclophotocoagulation  
This procedure is usually used to treat more aggressive 
or advanced open-angle glaucoma that has not 
responded to other therapies. Your doctor directs a 
laser through the sclera or endoscopically at the eye 
fluid-producing ciliary body. The procedure helps 
decrease the production of fluid and lower eye 
pressure. Patients often need multiple treatments
44
. 
Incisional surgery 
Incisional surgery is use in cases in which sufficient 
reduction of IOP cannot be achieved by other 
therapeutic means, or cases in which other appropriate 
means of treatment cannot be used because of adverse 
effects or non-compliance, and cases in which it is 
thought that sufficient reduction of IOP cannot be 
achieved by other therapeutic means.  
The indication for surgery must be made for each 
individual patient based on a comprehensive 
assessment of type of glaucoma, stage of glaucoma, the 
patient’s disease awareness, compliance, and the 
patient’s social background44. 
 
CONCLUSION 
Glaucoma is significant public health challenge 
because it is irreversible. The therapies available for 
glaucoma can prevent or slow vision loss, but once 
vision has been lost it cannot be restored. Early 
diagnosis and treatment can prevent vision loss from 
the disease. 
Treatment options for patients with glaucoma include 
medications, laser therapy, and incisional surgery. The 
risks and benefits of each type of treatment must be 
carefully considered to maximize the treatment’s 
benefits while minimizing adverse effects. There is 
need of advances in glaucoma treatment because 
proven medical and surgical therapies are limited in 
their capacity to stop glaucoma progression. 
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